Kapak Resmi

On the Regulatory Approval Pathway of Biosimilar Products

Biosimilars (or follow-on biologics) are a new class of medicine which enters the market subsequent to a previously approved version. They have demonstrated similarity to innovator biologic products in terms of quality, safety, and efficacy. The EMA has taken the lead in the regulatory approval fram...

Kaydedildi:

Detaylı Bibliyografya
Asıl Yazarlar:	Jun Wang (Yazar), Shein-Chung Chow (Yazar)
Materyal Türü:	Kitap
Baskı/Yayın Bilgisi:	MDPI AG, 2012-03-01T00:00:00Z.
Konular:	article
Online Erişim:	Connect to this object online.
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller

The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA
Yazar:: Ioana Gherghescu, ve diğerleri
Baskı/Yayın Bilgisi: (2020)

Analysis of the Regulatory Science Applied to a Single Portfolio of Eight Biosimilar Product Approvals by Four Key Regulatory Authorities
Yazar:: Beverly Ingram, ve diğerleri
Baskı/Yayın Bilgisi: (2021)

Ten years of biosimilars in Europe: development and evolution of the regulatory pathways
Yazar:: Schiestl M, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Biosimilars: State of Clinical and Regulatory Science
Yazar:: Agnes Victoria Klein, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

The Labyrinth of Product Development and Regulatory Approvals in Liquid Biopsy Diagnostics
Yazar:: Federico M. Goodsaid
Baskı/Yayın Bilgisi: (2019)

Biosimilars: Current regulatory perspective and challenges
Yazar:: Diwakar Jha, ve diğerleri
Baskı/Yayın Bilgisi: (2013)

A Regulatory Perspective on Biosimilar Medicines
Yazar:: Marta Agostinho Cordeiro, ve diğerleri
Baskı/Yayın Bilgisi: (2024)

Proposal of International Council for Harmonization (ICH) Guideline for the Approval of Biosimilars
Yazar:: Sarfaraz K. Niazi, ve diğerleri
Baskı/Yayın Bilgisi: (2023)

Current regulatory and market environment for biosimilars in Serbia
Yazar:: Pejović Gordana, ve diğerleri
Baskı/Yayın Bilgisi: (2014)

Biosimilars in Oncology: Latest Trends and Regulatory Status
Yazar:: Deeksha Joshi, ve diğerleri
Baskı/Yayın Bilgisi: (2022)

Regulatory reliance to approve new medicinal products in Latin American and Caribbean countries
Yazar:: Carlos E. Durán, ve diğerleri
Baskı/Yayın Bilgisi: (2021)

An Overview of Biosimilars-Development, Quality, Regulatory Issues, and Management in Healthcare
Yazar:: Filipa Mascarenhas-Melo, ve diğerleri
Baskı/Yayın Bilgisi: (2024)

The FDA's New Guideline "Generally Accepted Scientific Knowledge" (GASK): An Opportunity to Expedite the Approval of Biosimilars
Yazar:: Sarfaraz K. Niazi
Baskı/Yayın Bilgisi: (2023)

Creating China's Biosimilar Drugs Regulatory System: A Calculated Approach
Yazar:: Jianhong Yang, ve diğerleri
Baskı/Yayın Bilgisi: (2022)

Biological medicinal products: reference and biosimilar products - selected issues
Yazar:: Bartosz Kobuszewski
Baskı/Yayın Bilgisi: (2021)

Ten years experience with the first approved biosimilar recombinant human growth hormone drug in normal clinical practice
Yazar:: Juan Pedro López-Siguero, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Biosimilars: A Comparative Study of Regulatory, Safety and Pharmacovigilance Monograph in the Developed and Developing Economies
Yazar:: Zarina Iqbal, ve diğerleri
Baskı/Yayın Bilgisi: (2022)

Mesenchymal Stem Cell Therapies Approved by Regulatory Agencies around the World
Yazar:: Luis E. Fernández-Garza, ve diğerleri
Baskı/Yayın Bilgisi: (2023)

Regulatory histories of recently withdrawn ovarian cancer treatment indications of 3 PARP inhibitors in the US and Europe: lessons for the accelerated approval pathway
Yazar:: Mahnum Shahzad, ve diğerleri
Baskı/Yayın Bilgisi: (2024)

Regulatory lessons from China's COVID-19 vaccines development and approval policies
Yazar:: Jingshu Yang, ve diğerleri
Baskı/Yayın Bilgisi: (2022)

Access to Chagas disease treatment in the United States after the regulatory approval of benznidazole.
Yazar:: Kota Yoshioka, ve diğerleri
Baskı/Yayın Bilgisi: (2020)

Emerging technology trends in regulatory approvals of cancer immunotherapy drugs by the FDA and EMA
Yazar:: Maryam Monajati, ve diğerleri
Baskı/Yayın Bilgisi: (2024)

Comparison of BRICS-TM Countries' Biosimilar Regulatory Frameworks With Australia, Canada and Switzerland: Benchmarking Best Practices
Yazar:: Hasumati Rahalkar, ve diğerleri
Baskı/Yayın Bilgisi: (2021)

Biosimilars
Baskı/Yayın Bilgisi: (2022)

Biosimilars
Yazar:: Emel Bülbül Başkan
Baskı/Yayın Bilgisi: (2022)

Small molecule protein kinase inhibitors approved by regulatory agencies outside of the United States
Yazar:: Robert Roskoski Jr
Baskı/Yayın Bilgisi: (2023)

Budget Impact Analysis of Biosimilar Products in Spain in the Period 2009-2019
Yazar:: Manuel García-Goñi, ve diğerleri
Baskı/Yayın Bilgisi: (2021)

Regulatory Affairs 101: Introduction to Expedited Regulatory Pathways
Yazar:: Erica M. Cox, ve diğerleri
Baskı/Yayın Bilgisi: (2020)

Concepts and Challenges of Biosimilars in Breast Cancer: The Emergence of Trastuzumab Biosimilars
Yazar:: Alina Uifălean, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Biosimilars in Europe
Baskı/Yayın Bilgisi: (2023)

A Comprehensive Map of FDA-Approved Pharmaceutical Products
Yazar:: Hao Zhong, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Analytical and Functional Similarity of the Biosimilar Candidate ABP 654 to Ustekinumab Reference Product
Yazar:: Greg Cantin, ve diğerleri
Baskı/Yayın Bilgisi: (2023)

Tumor Growth Dynamic Modeling in Oncology Drug Development and Regulatory Approval: Past, Present, and Future Opportunities
Yazar:: Nidal Al‐Huniti, ve diğerleri
Baskı/Yayın Bilgisi: (2020)

Current State of Human Gene Therapy: Approved Products and Vectors
Yazar:: Aladdin Y. Shchaslyvyi, ve diğerleri
Baskı/Yayın Bilgisi: (2023)

Biosimilars in pemphigus vulgaris
Yazar:: Sharmila Patil, ve diğerleri
Baskı/Yayın Bilgisi: (2014)

Biosimilars - drugs of the future
Yazar:: E. A. Eltcova, ve diğerleri
Baskı/Yayın Bilgisi: (2014)

Generics and biosimilars in oncology
Yazar:: I. A. Gopienko, ve diğerleri
Baskı/Yayın Bilgisi: (2020)

Comparison of pharmacogenomic information for drug approvals provided by the national regulatory agencies in Korea, Europe, Japan, and the United States
Yazar:: Mijin Lee, ve diğerleri
Baskı/Yayın Bilgisi: (2023)

Population pharmacokinetic modeling and simulation of maribavir to support dose selection and regulatory approval in adolescents with posttransplant refractory cytomegalovirus
Yazar:: Kefeng Sun, ve diğerleri
Baskı/Yayın Bilgisi: (2023)

Quality, Non-clinical and Clinical Considerations for Biosimilar Monoclonal Antibody Development: EU, WHO, USA, Canada, and BRICS-TM Regulatory Guidelines
Yazar:: Hasumati Rahalkar, ve diğerleri
Baskı/Yayın Bilgisi: (2018)